Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRB | P09619 | 1/20 | 0.43 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.43 |
| ▸ | TGFBR1 | P36897 | 13/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.37 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.37 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.37 |
| ▸ | MTOR | P42345 | 1/20 | 0.36 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.36 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.36 |
| ▸ | PIP5K1C | O60331 | 1/20 | 0.36 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.36 |
| ▸ | PI4KA | P42356 | 1/20 | 0.36 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.36 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.36 |
| ▸ | MAP3K11 | Q16584 | 1/20 | 0.35 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.35 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25084915 | 1.00 | PDGFRB (0.43) | PDGFRBPDGFRATGFBR1HPGDMAPK14 | |
| SCHEMBL25084910 | 0.87 | TGFBR1 (0.45) | TGFBR1HPGDMAPK14MTOR | |
| SCHEMBL30156722 | 0.87 | TGFBR1 (0.45) | TGFBR1HPGDMAPK14MTOR | |
| SCHEMBL25085062 | 0.87 | TGFBR1 (0.45) | TGFBR1MAPK14MTOR | |
| SCHEMBL30156063 | 0.87 | TGFBR1 (0.45) | TGFBR1MAPK14MTOR | |
| SCHEMBL25084848 | 0.87 | TGFBR1 (0.45) | PDGFRBPDGFRATGFBR1MAPK14MTOR | |
| SCHEMBL30155996 | 0.87 | TGFBR1 (0.45) | PDGFRBPDGFRATGFBR1MAPK14MTOR | |
| SCHEMBL30156447 | 0.86 | TGFBR1 (0.43) | TGFBR1MAPK14MTOR | |
| SCHEMBL25084909 | 0.86 | TGFBR1 (0.43) | TGFBR1MAPK14MTOR | |
| SCHEMBL25084880 | 0.85 | CYP2A6 (0.46) | PDGFRBPDGFRATGFBR1MAPK14MTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11590116-B2 | Substituted pyridines and methods of use | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11590116-B2 | Substituted pyridines and methods of use | ALK, ACVR1, ACVR2A | PDGFRB 17/4885PDGFRA 44/4885TGFBR1 211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.